Chemed's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Chemed (CHE) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Chemed vs Its Competitors
- TTM: Trailing 12-month revenue of 2,661M vs 176,171M combined for its competitors (1.5% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+3.9% annualized vs trailing 12 months), vs accelerating (+6.8%) for its tracked peer group.
- Growth: Chemed generated 10.6% revenue growth year over year in Q3 2026, vs 26.5% for its competitors combined.
- Profitability: Its 10.4% net margin compares with 1.4% for the peer group.
- Scale: Chemed ranks #9 of 51 companies by market capitalization in the Healthcare Facilities industry, holding 2.5% of industry market cap.
- Peer revenue share: Chemed accounted for 1.5% of combined revenue among its tracked peer group, down from 1.7% a year earlier.
- Peer differentiation: Revenue per employee of $0.17M compares with $0.69M for the peer group (0.2x).
- Structure: Chemed operates in the following segments: Segment Vitas, Segment Roto Rooter.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CHE Sales vs. its Competitors, Q3 2026
Chemed reported revenue growth of 10.57 % year on year in Q3 2026, below its competitors' combined revenue growth of 26.49 %.
With a net margin of 10.37 %, Chemed achieved higher profitability than its competitors (1.43 %).
Chemed generated 1.45 % of the combined sales of its peer group, down from 1.65 % a year earlier.
API endpoints for this dataset
Chemed vs. its Competitors, Q3 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Chemed reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Chemed and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Chemed Corporation | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (8) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Chemed's competitor groups requires a Commercial License.
For context: the Healthcare Facilities industry grew revenue 14.7% year over year, combined, vs 10.6% for Chemed. Chemed's share of combined industry revenue moved from 0.60% to 0.58%, a loss of 0.02 percentage points.
Chemed's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Chemed Corporation | Yes | Yes | No | No |
| Competitors combined (14) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 75.00 % (6 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CHE Stock Performance relative to its Competitors
CHE Stock Performance relative to Similar-Size Competitors
CHE Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Humana Inc | 282.9% | Outperformed |
| 2 | Aveanna Healthcare Holdings Inc | 282.9% | Outperformed |
| 3 | Quipt Home Medical Corp | 282.9% | Outperformed |
| 4 | Viemed Healthcare Inc | 282.9% | Outperformed |
| 5 | Healthcare Services Group Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Chemed's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Chemed's Comment on Competition and Industry Peers
Publicly Traded Peers of Chemed Corporation
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Chemed Corporation |
7,067.42 | 2,661.04 |
 Welltower Inc |
186,725.26 | 13,793.30 |
 Humana Inc |
51,560.05 | 154,185.00 |
 Ensign Group Inc |
10,799.08 | 5,674.31 |
 Option Care Health Inc |
4,863.94 | 5,692.93 |
 Amedisys Inc |
3,361.86 | 2,402.37 |
| SUBTOTAL | 276,436.16 | 198,380.25 |
Sign in to see all competitors of Chemed Corporation.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Chemed Corporation versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Chemed's Competitors Named by the Company
Competitive relationships identified from Chemed reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| VITAS | Company report | 85% |
| Amedisys Inc | Company report | 85% |
| Option Care Health Inc | Company report | 85% |
| Addus Homecare Corp | Company report | 85% |
| Lhc Group Inc | Company report | 85% |
| Healthcare Services Group Inc | Company report | 85% |
| Enhabit Inc | Company report | 85% |
| Aveanna Healthcare Holdings Inc | Company report | 85% |
| Brookdale Senior Living Inc | Company report | 85% |
| Clearday Inc | Company report | 85% |
| Viemed Healthcare Inc | Company report | 85% |
| Modivcare Inc | Company report | 85% |
| Humana Inc | Company report | 85% |
| Ensign Group Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Chemed's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Chemed's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Chemed Corporation | Segment Vitas 66.20 % |
| Welltower Inc | Senior Housing - Operating 84.10 % |
| Humana Inc | Insurance 94.97 % |
| Ensign Group Inc | Skilled Services 95.82 % |
| Option Care Health Inc | Reportable 100.00 % |
| Aveanna Healthcare Holdings Inc | Private Duty Services 82.67 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Chemed's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Chemed Corporation | 7,067 | 168,303 | 17,861 |
| Welltower Inc | 186,725 | 19,372,612 | 2,454,900 |
| Humana Inc | 51,560 | 2,299,210 | 18,849 |
| Ensign Group Inc | 10,799 | 123,354 | 8,682 |
| Option Care Health Inc | 4,864 | 688,717 | 25,354 |
| Amedisys Inc | 3,362 | 126,440 | 4,309 |
| PEERS TOTAL | 269,369 | 691,297 | 12,262 |
Chemed's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Welltower Inc | United States 60.91 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Chemed's Position in Industry Market Structure
Market-capitalization share and concentration across all 48 companies in Chemed's industry classification, broader than the peer set above. Market cap in millions of $.Chemed ranks #9 of 48 companies by market capitalization in its industry, holding 2.51 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,836, indicating a moderately concentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Hca Healthcare Inc | 111,528 | 40.08 % |
| 2 | Tenet Healthcare Corp | 24,456 | 8.79 % |
| 3 | Brightspring Health Services Inc | 14,994 | 5.39 % |
| 4 | Encompass Health Corporation | 13,794 | 4.96 % |
| 5 | Davita Inc | 1,234 | 5.2% |
| 6 | Universal Health Services Inc | 1,234 | 5.2% |
| 7 | Ensign Group Inc | 1,234 | 5.2% |
| 8 | Pacs Group Inc | 1,234 | 5.2% |
| 9 | Chemed Corporation | 6,991 | 2.51 % |
| 10 | Fresenius Medical Care Ag | 1,234 | 5.2% |
Market cap and industry share for the rest of Chemed's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-09.
Chemed's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 4 | Encompass Health Corporation | 13,794 | 19.88 % |
| 5 | Davita Inc | 12,627 | 57.21 % |
| 6 | Universal Health Services Inc | 11,793 | -13.05 % |
| 7 | Ensign Group Inc | 10,755 | -1.15 % |
| 8 | Pacs Group Inc | 1,234 | 12.3% |
| 9 | Chemed Corporation | 6,991 | 23.02 % |
| 10 | Fresenius Medical Care Ag | 1,234 | 12.3% |
| 11 | Hims and Hers Health Inc | 1,234 | 12.3% |
| 12 | Concentra Group Holdings Parent Inc | 1,234 | 12.3% |
| 13 | Option Care Health Inc | 1,234 | 12.3% |
| 14 | Sotera Health Company | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Chemed's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-09. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Chemed's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Healthcare Facilities industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (113 companies). See the full Healthcare Facilities industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 33.65 % | 34.25 % (avg) | -0.6 pp |
| Operating Margin | 13.94 % | industry median | +4.0 pp |
| EBITDA Margin | 17.25 % | 3.04 % (avg) | +14.2 pp |
| Capital Intensity (Capex / Revenue) | 2.54 % | 3.79 % (avg) | -1.3 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Chemed's Valuation vs Competitive Position
Valuation multiples vs the Healthcare Facilities industry average (113 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Healthcare Facilities industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 24.9x | 21.2x | +3.7x |
| EV / EBITDA | 14.9x | 14.4x | +0.5x |
| P/B | 7.7x | 3.1x | +4.6x |
| Return on Equity | 32.10 % | industry aggregate | -63.61 % |
| Return on Invested Capital | 16.41 % | 1.98 % (avg) | 14.43 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Chemed's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 6.26 % | 8.75 % | 7.27 % | 3.66 % | -0.43 % | 6.06 % | 7.37 % | 4.06 % |
| Operating Margin | 13.67 % | 13.28 % | 18.74 % | 19.21 % | 16.09 % | 15.04 % | 15.07 % | 13.37 % |
| Return on Invested Capital | 18.38 % | 16.08 % | 20.46 % | 20.14 % | 18.18 % | 14.59 % | 13.37 % | 13.12 % |
| P/E | 24.0x | 33.1x | 26.0x | 25.1x | 30.4x | 31.2x | 28.4x | 23.9x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Chemed's Strategic Group Map
Chemed is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Chemed's trailing-12-month revenue growth of 5.2% and operating margin of 13.9% compares with an average of 8.0% growth and 12.6% margin across its 8 closest peers by combined growth, margin and ROIC -- Chemed sits below that peer average on growth and above it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Chemed's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Chemed falls in the Dog quadrant: relative market share of 0.06x vs its largest competitor, in an industry growing revenue 5.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution. A caveat worth reading alongside this chart: Hca Healthcare Inc alone holds 40% of this industry's market cap. In an industry this dominated by one leader, the framework will place nearly every OTHER company in "Dog" or "Question Mark" purely because relative share is measured against that leader, regardless of how strong those other companies actually are on their own fundamentals. Check the Profitability, Valuation and Financial Strength sections above before treating this quadrant label as a verdict.
Chemed's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Moderate | Industry HHI of 1,836 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 2.54 % vs industry average 3.79 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Chemed's dedicated Suppliers and Customers pages, not here.
Chemed's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Chemed falls in the Medium attractiveness / Medium strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Chemed's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+3.9% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 63.6 points below the industry aggregate.
- Low relative market share vs the industry leader (0.06x).
Opportunities
No rule matched.
Threats
- Industry dominated by Hca Healthcare Inc , holding 40.08 % of industry market cap.
Methodology: see Methodology: SWOT Analysis.
Chemed's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Chemed Corporation | 0.14 | 0.98 | 0.13 |
| Welltower Inc | 1.37 | 3.09 | 0.36 |
| Humana Inc | 0.32 | 1.93 | 0.71 |
| Ensign Group Inc | 0.46 | 1.34 | 0.05 |
| Option Care Health Inc | 0.29 | 1.54 | 0.88 |
| Amedisys Inc | 0.59 | 1.27 | 0.30 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Chemed's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Chemed Corporation | Q3 2026 | +10.6 % | +11.5 % |
| Welltower Inc | Q3 2026 | +38.4 % | +47.0 % |
| Humana Inc | Q3 2026 | +26.1 % | -16.5 % |
| Ensign Group Inc | Q3 2026 | +14.5 % | +24.3 % |
| Option Care Health Inc | Q2 2026 | +1.9 % | +6.7 % |
| Amedisys Inc | Q2 2025 | +5.2 % | -10.8 % |
| PEERS TOTAL | +23.5 % | +19.8 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Chemed's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Chemed Corporation | Q3 2026 | +7.0 % | +7.8 % |
| Welltower Inc | Q3 2026 | +42.3 % | +144.7 % |
| Humana Inc | Q3 2026 | - | +1.5 % |
| Ensign Group Inc | Q3 2026 | +11.7 % | - |
| Option Care Health Inc | Q2 2026 | +2.5 % | +21.8 % |
| Amedisys Inc | Q2 2025 | +6.6 % | -41.1 % |
Chemed's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Chemed Corporation | 17.73% | 20.46% | 32.10% |
| Welltower Inc | 2.51% | 2.52% | 3.78% |
| Humana Inc | 2.31% | 3.77% | 6.78% |
| Ensign Group Inc | 7.00% | 5.94% | 16.62% |
| Option Care Health Inc | 6.12% | 7.99% | 15.83% |
| Amedisys Inc | 3.77% | 4.60% | 6.68% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Chemed's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Chemed Corporation | 25.96 | 2.66 |
| Welltower Inc | 107.08 | 13.54 |
| Humana Inc | 41.74 | 0.33 |
| Ensign Group Inc | 27.06 | 1.90 |
| Option Care Health Inc | 24.01 | 0.85 |
| Amedisys Inc | 36.99 | 1.40 |
| PEERS AVERAGE | 73.64 | 1.39 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.